0000899243-22-007038.txt : 20220218
0000899243-22-007038.hdr.sgml : 20220218
20220218170945
ACCESSION NUMBER: 0000899243-22-007038
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220216
FILED AS OF DATE: 20220218
DATE AS OF CHANGE: 20220218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Waksal Harlan
CENTRAL INDEX KEY: 0001449008
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39273
FILM NUMBER: 22653797
MAIL ADDRESS:
STREET 1: WAKSAL CONSULTING LLC
STREET 2: 7 NORTH WILLOW STREET, SUITE 6
CITY: MONTCLAIR
STATE: NJ
ZIP: 07042
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001327273
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-373-4600
MAIL ADDRESS:
STREET 1: 480 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: 480 Biomedical, Inc.
DATE OF NAME CHANGE: 20120927
FORMER COMPANY:
FORMER CONFORMED NAME: Arsenal Vascular, Inc.
DATE OF NAME CHANGE: 20110826
FORMER COMPANY:
FORMER CONFORMED NAME: Arsenal Medical, Inc.
DATE OF NAME CHANGE: 20090414
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-16
0
0001327273
Lyra Therapeutics, Inc.
LYRA
0001449008
Waksal Harlan
C/O LYRA THERAPEUTICS, INC.
480 ARSENAL WAY
WATERTOWN
MA
02472
1
1
0
0
Executive Chair
Stock Option
4.21
2022-02-16
4
A
0
520000
0.00
A
2032-02-15
Common Stock
520000
520000
D
On February 16, 2022, the Reporting Person was granted an option to purchase 520,000 shares of common stock. The option vests and becomes exercisable as to 173,333 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 173,333 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 173,334 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date.
/s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D.
2022-02-18